Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DeCode Debate

This article was originally published in Start Up

Executive Summary

In Iceland, public debate has broken out about deCode Genetics' commercial rights to a database of medical information about the country's population. Will Roche, which in 1998 signed a $200+ million agreement with deCode to pursue genetic leads into cardiovascular neurological and metabolic diseases, get all it bargained for?

You may also be interested in...



Roche and DeCode Turn To Diagnostics

Roche Diagnostics has signed a new five-year-alliance with deCode Genetics, in a move that suggests the preliminary success of an earlier agreement between the companies. While the earlier deal, signed in 1998, revolves around finding pharmaceutical targets, the new agreement aims to identify and validate diagnostics targets based on genes associated with common diseases.

The Population Genetics Equation: Data + Product Focus = Funding

Given the ho-hum attitude investors have shown toward population genetics, Xenon Genetics' $45 million private placement is notable. Now that the dust has settled on two of the older companies in the field, deCode Genetics and Gemini Genomics, which went public in July 2000, it is clear that the market gives them little technology value. But Xenon believes it can differentiate itself by the breadth of its data, which come from 28 populations, and its product-oriented approach.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel